首页> 外文期刊>American Journal of Nephrology >End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases
【24h】

End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases

机译:由于纤维性肾小球肾炎和免疫球蛋白样肾小球病导致的终末期肾脏疾病-连续66例ANZDATA登记病例的结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Fibrillary glomerulonephritis (FGN) and immunotactoid glomerulopathy (IG) are uncommon and characterised by non-amyloid fibrillary glomerular deposits. The aim of this study was to investigate characteristics and outcomes of patients undergoing renal replacement therapy (RRT) for end-stage kidney disease (ESKD) secondary to FGN and IG. Methods: All ESKD patients who commenced RRT in Australia and New Zealand 1 January 1990 to 31 December 2010 were included. Outcomes were assessed by Kaplan-Meier, multivariate logistic-regression analysis and multivariable Cox proportional-hazards survival analysis. Results: Of 45,216 individuals with ESKD, 55 (0.12%) had FGN and 11 (0.02%) had IG. The median survival of FGN patients on dialysis (5.63 years, 95% Cl 3.31-7.96) was not significantly different from patients with other ESKD causes (median 4.01 years, 95% Cl 4.34-4.47; log-rank 1.32, p = 0.25), but was significantly longer than that of IG patients (median 2.93 years, 95% Cl 0.00-6.17; log-rank 4.8, p = 0.03). Thirteen (24%) FGN patients received 13 renal-allografts, 4 (36%) IG patients received 4 renal-allografts and 11,528 (26%) other ESKD patients received 12,278 renal-allografts. FGN patients experienced comparable outcomes to other ESKD patients for both 10-year patient survival (100 vs. 84%, p = 0.93) and renal-allograft survival (67 vs. 76%, p = 0.06). For IG, the median follow-up was 3.66 years with 75% patient survival and 100% renal-allograft survival. One (8%) FGN patient and 1 (25%) IG patient experienced recurrent FGN and IG respectively in their allograft. Conclusion: Patients with FGN have comparable dialysis and renal transplant outcomes to patients with other causes of ESKD. IG patients have inferior survival on dialysis, although renal transplant outcomes are acceptable. Disease recurrence in renal-allografts was low for both FGN and IG. (C) 2015 S. Karger AG, Basel
机译:背景:原发性肾小球性肾小球肾炎(FGN)和免疫类触觉性肾小球病(IG)以非淀粉样纤维状肾小球性肾小球沉积为特征。这项研究的目的是调查接受继发于FGN和IG的终末期肾脏疾病(ESKD)的肾脏替代疗法(RRT)的患者的特征和结局。方法:纳入1990年1月1日至2010年12月31日在澳大利亚和新西兰开始RRT的所有ESKD患者。结果通过Kaplan-Meier,多元逻辑回归分析和多变量Cox比例风险生存分析进行评估。结果:在45216名ESKD患者中,有55名(0.12%)患有FGN,而11名(0.02%)患有IG。透析的FGN患者的中位生存期(5.63年,95%Cl 3.31-7.96)与其他ESKD原因患者(中位数4.01年,95%Cl 4.34-4.47; log-rank 1.32,p = 0.25)无显着差异,但显着长于IG患者(中位2.93岁,95%Cl 0.00-6.17;对数排名4.8,p = 0.03)。 13例(24%)FGN患者接受了13例肾移植,4例(36%)IG患者接受了4例肾移植,其他11528例(26%)ESKD患者接受了12278例肾移植。 FGN患者的10年生存率(100 vs. 84%,p = 0.93)和肾移植同体移植生存率(67 vs. 76%,p = 0.06)与其他ESKD患者可比。对于IG,中位随访时间为3.66年,患者生存率为75%,肾同种异体移植生存率为100%。 1名(8%)FGN患者和1名(25%)IG患者在同种异体移植物中分别经历了复发性FGN和IG。结论:FGN患者的透析和肾移植结果与其他原因的ESKD患者相当。尽管肾移植的结果可以接受,但IG患者的透析生存期较差。对于FGN和IG,肾同种异体移植的疾病复发率都很低。 (C)2015 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号